Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  British American Tobacco Plc    BATS   GB0002875804

BRITISH AMERICAN TOBACCO PLC

(BATS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

British American Tobacco : working on COVID-19 vaccine using tobacco leaves

share with twitter share with LinkedIn share with facebook
share via e-mail
04/01/2020 | 05:20am EDT

British American Tobacco, the maker of Dunhill and Lucky Strike cigarettes, said on Wednesday its U.S. biotech unit was working on a potential vaccine for COVID-19 using proteins extracted from tobacco leaves.

Kentucky BioProcessing (KBP), the unit developing the vaccine, could produce between 1 million and 3 million doses per week starting in June, the company said, with support from government agencies and the right manufacturers.

British American Tobacco said KBP, a division of BAT's U.S. unit Reynolds American Inc, would develop the vaccine on a not-for-profit basis.

The vaccine, currently undergoing pre-clinical testing, uses a cloned portion of COVID-19's genetic sequence to create an antigen that is then inserted into tobacco plants for reproduction.

Once harvested, the antigens - substances that induce an immune response in the body - are extracted and purified and inserted into the body to fight the virus, the company said, adding that the formulation it is developing is stable at room temperature, unlike conventional vaccines which often require refrigeration.

KBP made headlines a few years back when it said https://www.reuters.com/article/health-ebola-tobacco-idINKBN0G608V20140806 it had created an effective treatment against Ebola called ZMapp, in conjunction with California-based Mapp Biopharmaceuticals. The drug is yet to get U.S. Food and Drug Administration approval.

"We believe we have made a significant break-through with our tobacco plant technology platform and stand ready to work with governments and all stakeholders to help win the war against COVID-19," David O'Reilly, director of Scientific Research at BAT, said in a statement.

BAT said it was working with the U.S. Food and Drug Administration on the next steps and was also engaged with U.K. health authorities to bring its vaccine to clinical studies as soon as possible.

(Reporting by Siddharth Cavale in Bengaluru; Editing by Bernard Orr)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BRITISH AMERICAN TOBACCO P
06/01UK's Largest Pension Fund to Sell Out of Coal, Tobacco and Weapons -- Financi..
DJ
05/20BRITISH AMERICAN TOBACCO : Revenues to dip as illicit cigarette trade rises in P..
AQ
05/15BAT says potential COVID-19 vaccine using tobacco leaves ready for human tria..
RE
05/01BRITISH AMERICAN TOBACCO P.L.C : Chairman's AGM Statement - 2020 outlook
AQ
04/30BAT : JP Morgan maintains a Buy rating
MD
04/30BRITISH AMERICAN TOBACCO : BAT sticks to earnings forecast, flags first signs of..
RE
04/30BRITISH AMERICAN TOBACCO : BAT sticks to earnings forecast, flags first signs of..
RE
04/30BRITISH AMERICAN TOBACCO : Expects 2Q Stock Reduction, Revenue Fall
DJ
04/30BRITISH AMERICAN TOBACCO : Chairman's AGM Statement - 2020 outlook
PU
04/30BRITISH AMERICAN TOBACCO PLC : Monthly statement on outstanding equity shares an..
CO
More news
Financials
Sales 2020 26 301 M 33 013 M 33 013 M
Net income 2020 7 280 M 9 137 M 9 137 M
Net Debt 2020 40 545 M 50 893 M 50 893 M
P/E ratio 2020 9,97x
Yield 2020 6,74%
Capitalization 74 101 M 93 366 M 93 011 M
EV / Sales 2019
EV / Sales 2020 4,36x
Nbr of Employees 64 099
Free-Float 92,8%
Chart BRITISH AMERICAN TOBACCO PLC
Duration : Period :
British American Tobacco Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRITISH AMERICAN TOBACCO P
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 3 678,48 GBp
Last Close Price 3 241,50 GBp
Spread / Highest target 48,1%
Spread / Average Target 13,5%
Spread / Lowest Target -39,9%
EPS Revisions
Managers
NameTitle
Jack Marie Henry David Bowles Chief Executive Officer & Executive Director
Richard George William Burrows Chairman
Alan Davy Operations Director
Tadeu Luiz Marroco Executive Director & Finance Director
David O'Reilly Director-Research & Science
Sector and Competitors
1st jan.Capitalization (M$)
BRITISH AMERICAN TOBACCO PLC0.31%91 752
PHILIP MORRIS INTERNATIONAL, INC.-13.35%114 807
ALTRIA GROUP, INC.-20.54%73 703
JAPAN TOBACCO INC.-11.55%35 436
ITC LIMITED-17.25%32 310
IMPERIAL BRANDS PLC-20.47%17 511